STRATEGIC ADVISORY BOARD

MGB brings together a truly world class team of advisors and is proud to include key inventors of the MGB anti-infective class from the University of Strathclyde.

Professor Colin J Suckling OBE, BSc, PhD, DSc, CChem, FRSC, FRSA, HonFRCPSEdin, FRCPSGlas, FHEA, FRSE Freeland Professor of Chemistry, University of Strathclyde                                                                                                                                                                          Together with his team he discovered and patented innovations related to the MGB Project. He was one of the first to emphasise the symbiosis of chemistry and biology. Pursuing this interaction recent research has created genuine therapeutic opportunities for the treatment of various diseases.

Professor Iain S Hunter BSc, PhD Dean of the Faculty of Science & Professor of Molecular Microbiology, University of Strathclyde.    Professor Hunter read Biochemistry at the University of Glasgow continued there for a PhD in Microbial Physiology. After 3 years as Research Fellow at Cambridge University's Biochemistry Department, he moved into the private sector with Pfizer Central Research, where he worked as Senior, then Principal Research Scientist, on molecular genetics and antibiotic discovery and strain improvement. Professor Hunter joined the University of Strathclyde in 1995 as a Professor of Molecular Microbiology and was appointed Dean of Science in 2008.

Professor Curtis Gemmell B.Sc. Ph.D. F.R.C.Path. is an internationally renowned leader in research into human bacterial pathogens with particular interests in antibiotic susceptibility, animal models of bacterial infection and the development of novel therapeutic agents. He spent most of his career at the Medical School of the University of Glasgow and retains a research interest in the pathogenicity of Staphylococcus aureus, its association with hospital acquired infection, epidemiology and molecular characterisation and expression of antibiotic resistance. He was formerly Director of the Scottish MRSA Reference Laboratory from its formation in 1997 until 2006 and has served on the Councils of several national and international societies and is currently Editor-in-Chief of Reviews in Medical Microbiology. Currently he is a Research Professor at the University of Strathclyde, Part-time Teaching Professor at the University of St Andrews and Director of in vivo simulations Ltd.                                                                                                                                                                                     

Professor David Scales     BSc, PhD, MSc, LLM, FIBiol, FRCPath.
Strategic & Preclinical Advisor - has more than 20 years experience in large pharmaceutical companies, having held a senior global positions in R&D within GlaxoWellcome. He moved into the biotechnology sector in 2000 working as R&D director for Strakan Ltd (now ProStrakan Group), Charterhouse Therapeutics Ltd and Antisoma plc before undertaking several CEO positions. He was a non-executive director of BIBRA International, Enhance Biotech Inc, and was a board member at the UK Public Health Laboratory Service. He has 3 degrees from London University and the Royal Postgraduate Medical School. He was awarded a Fellowship of the Royal College of Pathologists in 1993 and an LLM from the Cardiff Law School in 1995. He held visiting chairs at King's College and the School of Pharmacy at London University. He is currently CEO of GlycoForm Limited, an Oxford based biotech company.